Changes
On February 7, 2023 at 8:27:23 AM UTC, Chimwemwe Mkandawire:
-
No fields were updated. See the metadata diff for more details.
f | 1 | { | f | 1 | { |
2 | "author": "", | 2 | "author": "", | ||
3 | "author_email": "", | 3 | "author_email": "", | ||
4 | "creator_user_id": "c64e3919-2d1c-42bf-835b-e85a6be9792c", | 4 | "creator_user_id": "c64e3919-2d1c-42bf-835b-e85a6be9792c", | ||
5 | "groups": [], | 5 | "groups": [], | ||
6 | "id": "e58cea1f-d3f6-4200-b193-8dad003949ee", | 6 | "id": "e58cea1f-d3f6-4200-b193-8dad003949ee", | ||
7 | "isopen": false, | 7 | "isopen": false, | ||
8 | "license_id": "notspecified", | 8 | "license_id": "notspecified", | ||
9 | "license_title": "License not specified", | 9 | "license_title": "License not specified", | ||
10 | "maintainer": null, | 10 | "maintainer": null, | ||
11 | "maintainer_email": null, | 11 | "maintainer_email": null, | ||
12 | "metadata_created": "2023-02-07T08:26:47.108930", | 12 | "metadata_created": "2023-02-07T08:26:47.108930", | ||
n | 13 | "metadata_modified": "2023-02-07T08:27:23.131261", | n | 13 | "metadata_modified": "2023-02-07T08:27:23.621422", |
14 | "name": "malawi-integrated-hiv-program-report-2022-q1", | 14 | "name": "malawi-integrated-hiv-program-report-2022-q1", | ||
15 | "notes": "__Program performance highlights by the end of March 2022 | 15 | "notes": "__Program performance highlights by the end of March 2022 | ||
16 | include:__\r\n\r\n* Scale-up of integrated HIV services had reached | 16 | include:__\r\n\r\n* Scale-up of integrated HIV services had reached | ||
17 | the following number of sites:\r\n * __754__ static and __227__ | 17 | the following number of sites:\r\n * __754__ static and __227__ | ||
18 | outreach HIV testing sites.\r\n * __787__ (static) ART sites; | 18 | outreach HIV testing sites.\r\n * __787__ (static) ART sites; | ||
19 | __626__ of these started at least one pregnant or breastfeeding | 19 | __626__ of these started at least one pregnant or breastfeeding | ||
20 | woman.\r\n + __716__ sites with HIV-exposed children in | 20 | woman.\r\n + __716__ sites with HIV-exposed children in | ||
21 | follow-up.\r\n* __717,316__ persons were tested for HIV by a trained | 21 | follow-up.\r\n* __717,316__ persons were tested for HIV by a trained | ||
22 | provider and received their results; __149,358 (21%)__ accessed HIV | 22 | provider and received their results; __149,358 (21%)__ accessed HIV | ||
23 | testing for the first time; __567,958 (79%)__ were repeat testers and | 23 | testing for the first time; __567,958 (79%)__ were repeat testers and | ||
24 | __22,045 (4%)__ of these received confirmatory testing (after having | 24 | __22,045 (4%)__ of these received confirmatory testing (after having | ||
25 | tested positive in the past). __19,944 (3.0%)__ clients received a | 25 | tested positive in the past). __19,944 (3.0%)__ clients received a | ||
26 | positive result for the first time.\r\n* A total of __122,135__ people | 26 | positive result for the first time.\r\n* A total of __122,135__ people | ||
27 | received __202,946__ self-test kits; __98,800 (49%)__ of these were | 27 | received __202,946__ self-test kits; __98,800 (49%)__ of these were | ||
28 | for use by the recipient and __103,796 (49%)__ for onward distribution | 28 | for use by the recipient and __103,796 (49%)__ for onward distribution | ||
29 | to sex partners or other people.\r\n* __23,038 (92%)__ of __25,140__ | 29 | to sex partners or other people.\r\n* __23,038 (92%)__ of __25,140__ | ||
30 | blood units collected were screened for (at least) HIV, hepatitis B | 30 | blood units collected were screened for (at least) HIV, hepatitis B | ||
31 | and syphilis.\r\n* A cumulative total of __21,550__ clients were | 31 | and syphilis.\r\n* A cumulative total of __21,550__ clients were | ||
32 | referred for PrEP eligibility screening and __19,687 (91%)__ were | 32 | referred for PrEP eligibility screening and __19,687 (91%)__ were | ||
33 | found eligible. __17,086 (87%)__ were enrolled in PrEP and __10,784 | 33 | found eligible. __17,086 (87%)__ were enrolled in PrEP and __10,784 | ||
34 | (63%)__ clients were retained on PrEP at the end of the December | 34 | (63%)__ clients were retained on PrEP at the end of the December | ||
35 | 2021.\r\n* __167,127 (97%)__ of __173,413__ women at ANC had their HIV | 35 | 2021.\r\n* __167,127 (97%)__ of __173,413__ women at ANC had their HIV | ||
36 | status ascertained; __8,595 (6%)__ of these were HIV positive. | 36 | status ascertained; __8,595 (6%)__ of these were HIV positive. | ||
37 | __139,409 (95%)__ of __147,830__ at maternity had their HIV status | 37 | __139,409 (95%)__ of __147,830__ at maternity had their HIV status | ||
38 | ascertained __8,361 (6%)__ of these were HIV positive.\r\n* __19,687__ | 38 | ascertained __8,361 (6%)__ of these were HIV positive.\r\n* __19,687__ | ||
39 | patients started ART this quarter; __87%__ were classified as | 39 | patients started ART this quarter; __87%__ were classified as | ||
40 | asymptomatic / in WHO stage 1 and started under the \u201cTest & | 40 | asymptomatic / in WHO stage 1 and started under the \u201cTest & | ||
41 | Treat\u201d policy.\r\n* __909,284__ patients were alive and on ART by | 41 | Treat\u201d policy.\r\n* __909,284__ patients were alive and on ART by | ||
42 | end of March 2022.2 This means that __92%__ of the estimated | 42 | end of March 2022.2 This means that __92%__ of the estimated | ||
43 | __985,346__ HIV positive population was on ART. ART coverage was __78% | 43 | __985,346__ HIV positive population was on ART. ART coverage was __78% | ||
44 | (42,909/ 53,225)__ for children4 and __92% (866,375 / 932,121)__ for | 44 | (42,909/ 53,225)__ for children4 and __92% (866,375 / 932,121)__ for | ||
45 | adults.\r\n* __54,998 (93%)__ of viral load results from routine | 45 | adults.\r\n* __54,998 (93%)__ of viral load results from routine | ||
46 | monitoring were <1000 copies/ml. Viral suppression rates for routine | 46 | monitoring were <1000 copies/ml. Viral suppression rates for routine | ||
47 | samples among children (0-14 years) and adults (15+ years) were | 47 | samples among children (0-14 years) and adults (15+ years) were | ||
48 | __80%__ and __93%__, respectively.\r\n* __80%__ of adults and __81%__ | 48 | __80%__ and __93%__, respectively.\r\n* __80%__ of adults and __81%__ | ||
49 | of children were retained alive on ART at 12 months after | 49 | of children were retained alive on ART at 12 months after | ||
50 | initiation.5\r\n* Out of __906,149__ patients on first line adult ART | 50 | initiation.5\r\n* Out of __906,149__ patients on first line adult ART | ||
51 | __865,861 (97%)__ had transitioned to TDF/3TC/DTG and only __1,157 | 51 | __865,861 (97%)__ had transitioned to TDF/3TC/DTG and only __1,157 | ||
52 | (<1%)__ were on TDF/3TC/EFV.\r\n* __11,290 (>99%)__ of an estimated | 52 | (<1%)__ were on TDF/3TC/EFV.\r\n* __11,290 (>99%)__ of an estimated | ||
53 | __9,363__. HIV infected pregnant women in Malawi were on ART this | 53 | __9,363__. HIV infected pregnant women in Malawi were on ART this | ||
54 | quarter. __8,573 (76%)__ of these were already on ART when getting | 54 | quarter. __8,573 (76%)__ of these were already on ART when getting | ||
55 | pregnant and __2,753 (24%)__ started ART during | 55 | pregnant and __2,753 (24%)__ started ART during | ||
56 | pregnancy/delivery.\r\n* An additional __684__ breastfeeding women | 56 | pregnancy/delivery.\r\n* An additional __684__ breastfeeding women | ||
57 | (re-)started ART in WHO stage 1 or 2.\r\n* __86%__ and __82%__ of | 57 | (re-)started ART in WHO stage 1 or 2.\r\n* __86%__ and __82%__ of | ||
58 | women started while pregnant or breastfeeding were retained on ART at | 58 | women started while pregnant or breastfeeding were retained on ART at | ||
59 | 6 and 12 months after initiation, respectively.\r\n* __7,871 (7%)__ of | 59 | 6 and 12 months after initiation, respectively.\r\n* __7,871 (7%)__ of | ||
60 | infants discharged alive from maternity were known to be HIV exposed, | 60 | infants discharged alive from maternity were known to be HIV exposed, | ||
61 | __7,554 (96%)__ of these received ARV prophylaxis (nevirapine).\r\n* A | 61 | __7,554 (96%)__ of these received ARV prophylaxis (nevirapine).\r\n* A | ||
62 | total of __12,455__ HIV exposed children were newly enrolled for | 62 | total of __12,455__ HIV exposed children were newly enrolled for | ||
63 | follow-up this quarter; __10,250 (82%)__ of these were enrolled before | 63 | follow-up this quarter; __10,250 (82%)__ of these were enrolled before | ||
64 | age 2 months.\r\n* Out of the total __985,346__ estimated PLHIV by end | 64 | age 2 months.\r\n* Out of the total __985,346__ estimated PLHIV by end | ||
65 | March 2022:", | 65 | March 2022:", | ||
66 | "num_resources": 1, | 66 | "num_resources": 1, | ||
67 | "num_tags": 10, | 67 | "num_tags": 10, | ||
68 | "organization": { | 68 | "organization": { | ||
69 | "approval_status": "approved", | 69 | "approval_status": "approved", | ||
70 | "created": "2021-10-14T11:02:35.234558", | 70 | "created": "2021-10-14T11:02:35.234558", | ||
71 | "description": "The Department of HIV & AIDS (DHA) was established | 71 | "description": "The Department of HIV & AIDS (DHA) was established | ||
72 | in 2001, initially as a unit in the Department of Clinical Services, | 72 | in 2001, initially as a unit in the Department of Clinical Services, | ||
73 | to coordinate the biomedical HIV Program in Malawi. The department now | 73 | to coordinate the biomedical HIV Program in Malawi. The department now | ||
74 | carries responsibility for various HIV related programs including: | 74 | carries responsibility for various HIV related programs including: | ||
75 | sexually transmitted infections (STIs), prevention of mother to child | 75 | sexually transmitted infections (STIs), prevention of mother to child | ||
76 | transmission of HIV (PMTCT), and national voluntary male medical | 76 | transmission of HIV (PMTCT), and national voluntary male medical | ||
77 | circumcision program (VMMC). All these HIV program sub-sections are | 77 | circumcision program (VMMC). All these HIV program sub-sections are | ||
78 | linked to one robust monitoring and evaluation sub-section in the HIV | 78 | linked to one robust monitoring and evaluation sub-section in the HIV | ||
79 | and AIDS Department which technically operates under the Central | 79 | and AIDS Department which technically operates under the Central | ||
80 | Monitoring and Evaluation Department (CMED) of the Ministry of | 80 | Monitoring and Evaluation Department (CMED) of the Ministry of | ||
81 | Health.", | 81 | Health.", | ||
82 | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | 82 | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | ||
83 | "image_url": | 83 | "image_url": | ||
84 | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | 84 | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | ||
85 | "is_organization": true, | 85 | "is_organization": true, | ||
86 | "name": "dha", | 86 | "name": "dha", | ||
87 | "state": "active", | 87 | "state": "active", | ||
88 | "title": "Department of HIV & AIDS and Viral Hepatitis", | 88 | "title": "Department of HIV & AIDS and Viral Hepatitis", | ||
89 | "type": "organization" | 89 | "type": "organization" | ||
90 | }, | 90 | }, | ||
91 | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | 91 | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | ||
92 | "private": false, | 92 | "private": false, | ||
93 | "program_area": "Care and Treatment", | 93 | "program_area": "Care and Treatment", | ||
94 | "relationships_as_object": [], | 94 | "relationships_as_object": [], | ||
95 | "relationships_as_subject": [], | 95 | "relationships_as_subject": [], | ||
96 | "resources": [ | 96 | "resources": [ | ||
97 | { | 97 | { | ||
98 | "cache_last_updated": null, | 98 | "cache_last_updated": null, | ||
99 | "cache_url": null, | 99 | "cache_url": null, | ||
100 | "created": "2023-02-07T08:27:23.162496", | 100 | "created": "2023-02-07T08:27:23.162496", | ||
101 | "description": "", | 101 | "description": "", | ||
102 | "format": "PDF", | 102 | "format": "PDF", | ||
103 | "hash": "", | 103 | "hash": "", | ||
104 | "id": "44d5a99e-1745-4a4e-b973-37f45caad990", | 104 | "id": "44d5a99e-1745-4a4e-b973-37f45caad990", | ||
105 | "last_modified": "2023-02-07T08:27:23.121151", | 105 | "last_modified": "2023-02-07T08:27:23.121151", | ||
106 | "lfs_prefix": | 106 | "lfs_prefix": | ||
107 | "dha/malawi-integrated-hiv-program-report-2022-q1", | 107 | "dha/malawi-integrated-hiv-program-report-2022-q1", | ||
n | 108 | "metadata_modified": "2023-02-07T08:27:23.136567", | n | 108 | "metadata_modified": "2023-02-07T08:27:23.627492", |
109 | "mimetype": "application/pdf", | 109 | "mimetype": "application/pdf", | ||
110 | "mimetype_inner": null, | 110 | "mimetype_inner": null, | ||
111 | "name": "Malawi Integrated HIV Program Report 2022 Q1", | 111 | "name": "Malawi Integrated HIV Program Report 2022 Q1", | ||
112 | "package_id": "e58cea1f-d3f6-4200-b193-8dad003949ee", | 112 | "package_id": "e58cea1f-d3f6-4200-b193-8dad003949ee", | ||
113 | "position": 0, | 113 | "position": 0, | ||
114 | "resource_type": null, | 114 | "resource_type": null, | ||
115 | "sha256": | 115 | "sha256": | ||
116 | "73b958c795ec1deeb6743c3e3402da65885b9e26aa8b1e06b8ab904016cbf440", | 116 | "73b958c795ec1deeb6743c3e3402da65885b9e26aa8b1e06b8ab904016cbf440", | ||
117 | "size": 4197767, | 117 | "size": 4197767, | ||
118 | "state": "active", | 118 | "state": "active", | ||
119 | "url": | 119 | "url": | ||
120 | f45caad990/download/malawi_integrated_hiv_program_report_2022_q1.pdf", | 120 | f45caad990/download/malawi_integrated_hiv_program_report_2022_q1.pdf", | ||
121 | "url_type": "upload" | 121 | "url_type": "upload" | ||
122 | } | 122 | } | ||
123 | ], | 123 | ], | ||
t | 124 | "state": "draft", | t | 124 | "state": "active", |
125 | "tags": [ | 125 | "tags": [ | ||
126 | { | 126 | { | ||
127 | "display_name": "HTC", | 127 | "display_name": "HTC", | ||
128 | "id": "6a53fcf5-e774-4295-b9c3-32da8b896f9b", | 128 | "id": "6a53fcf5-e774-4295-b9c3-32da8b896f9b", | ||
129 | "name": "HTC", | 129 | "name": "HTC", | ||
130 | "state": "active", | 130 | "state": "active", | ||
131 | "vocabulary_id": null | 131 | "vocabulary_id": null | ||
132 | }, | 132 | }, | ||
133 | { | 133 | { | ||
134 | "display_name": "PMTCT-ART", | 134 | "display_name": "PMTCT-ART", | ||
135 | "id": "83bf82ef-383c-46e2-a80c-f3431b3f99e2", | 135 | "id": "83bf82ef-383c-46e2-a80c-f3431b3f99e2", | ||
136 | "name": "PMTCT-ART", | 136 | "name": "PMTCT-ART", | ||
137 | "state": "active", | 137 | "state": "active", | ||
138 | "vocabulary_id": null | 138 | "vocabulary_id": null | ||
139 | }, | 139 | }, | ||
140 | { | 140 | { | ||
141 | "display_name": "anc", | 141 | "display_name": "anc", | ||
142 | "id": "1e47aae6-8e3d-41e7-9b1a-778af0d2f23a", | 142 | "id": "1e47aae6-8e3d-41e7-9b1a-778af0d2f23a", | ||
143 | "name": "anc", | 143 | "name": "anc", | ||
144 | "state": "active", | 144 | "state": "active", | ||
145 | "vocabulary_id": null | 145 | "vocabulary_id": null | ||
146 | }, | 146 | }, | ||
147 | { | 147 | { | ||
148 | "display_name": "blood safety", | 148 | "display_name": "blood safety", | ||
149 | "id": "24fd7907-18be-4ad1-80ad-ba65da6a9707", | 149 | "id": "24fd7907-18be-4ad1-80ad-ba65da6a9707", | ||
150 | "name": "blood safety", | 150 | "name": "blood safety", | ||
151 | "state": "active", | 151 | "state": "active", | ||
152 | "vocabulary_id": null | 152 | "vocabulary_id": null | ||
153 | }, | 153 | }, | ||
154 | { | 154 | { | ||
155 | "display_name": "featured", | 155 | "display_name": "featured", | ||
156 | "id": "22f37483-07b1-400c-a6e5-16ff1153a217", | 156 | "id": "22f37483-07b1-400c-a6e5-16ff1153a217", | ||
157 | "name": "featured", | 157 | "name": "featured", | ||
158 | "state": "active", | 158 | "state": "active", | ||
159 | "vocabulary_id": null | 159 | "vocabulary_id": null | ||
160 | }, | 160 | }, | ||
161 | { | 161 | { | ||
162 | "display_name": "hiv", | 162 | "display_name": "hiv", | ||
163 | "id": "43013fde-ebf4-470e-9e5d-1a3aa939d404", | 163 | "id": "43013fde-ebf4-470e-9e5d-1a3aa939d404", | ||
164 | "name": "hiv", | 164 | "name": "hiv", | ||
165 | "state": "active", | 165 | "state": "active", | ||
166 | "vocabulary_id": null | 166 | "vocabulary_id": null | ||
167 | }, | 167 | }, | ||
168 | { | 168 | { | ||
169 | "display_name": "maternity", | 169 | "display_name": "maternity", | ||
170 | "id": "cd2b6dc5-5d1f-4a03-91da-9a279e193ed2", | 170 | "id": "cd2b6dc5-5d1f-4a03-91da-9a279e193ed2", | ||
171 | "name": "maternity", | 171 | "name": "maternity", | ||
172 | "state": "active", | 172 | "state": "active", | ||
173 | "vocabulary_id": null | 173 | "vocabulary_id": null | ||
174 | }, | 174 | }, | ||
175 | { | 175 | { | ||
176 | "display_name": "report", | 176 | "display_name": "report", | ||
177 | "id": "80c23033-8ff3-483d-8aa6-03e39b117372", | 177 | "id": "80c23033-8ff3-483d-8aa6-03e39b117372", | ||
178 | "name": "report", | 178 | "name": "report", | ||
179 | "state": "active", | 179 | "state": "active", | ||
180 | "vocabulary_id": null | 180 | "vocabulary_id": null | ||
181 | }, | 181 | }, | ||
182 | { | 182 | { | ||
183 | "display_name": "sti", | 183 | "display_name": "sti", | ||
184 | "id": "38222aa3-73ca-4ca8-8b42-9a5eb558af5a", | 184 | "id": "38222aa3-73ca-4ca8-8b42-9a5eb558af5a", | ||
185 | "name": "sti", | 185 | "name": "sti", | ||
186 | "state": "active", | 186 | "state": "active", | ||
187 | "vocabulary_id": null | 187 | "vocabulary_id": null | ||
188 | }, | 188 | }, | ||
189 | { | 189 | { | ||
190 | "display_name": "viral load", | 190 | "display_name": "viral load", | ||
191 | "id": "e385a0a4-1722-431f-a657-f9616a14bf6f", | 191 | "id": "e385a0a4-1722-431f-a657-f9616a14bf6f", | ||
192 | "name": "viral load", | 192 | "name": "viral load", | ||
193 | "state": "active", | 193 | "state": "active", | ||
194 | "vocabulary_id": null | 194 | "vocabulary_id": null | ||
195 | } | 195 | } | ||
196 | ], | 196 | ], | ||
197 | "title": "Malawi Integrated HIV Program Report 2022 Q1", | 197 | "title": "Malawi Integrated HIV Program Report 2022 Q1", | ||
198 | "type": "dataset", | 198 | "type": "dataset", | ||
199 | "url": null, | 199 | "url": null, | ||
200 | "version": null, | 200 | "version": null, | ||
201 | "year": "2022" | 201 | "year": "2022" | ||
202 | } | 202 | } |